These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9201668)

  • 41. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.
    Rothschild AJ; Samson JA; Bessette MP; Carter-Campbell JT
    J Clin Psychiatry; 1993 Sep; 54(9):338-42. PubMed ID: 8104930
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group.
    Demyttenaere K; Van Ganse E; Gregoire J; Gaens E; Mesters P
    Int Clin Psychopharmacol; 1998 Jan; 13(1):11-7. PubMed ID: 9988362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluoxetine: new indication. Depression in children: too many uncertainties.
    Prescrire Int; 2008 Oct; 17(97):186-7. PubMed ID: 19534039
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical efficacy of reboxetine in major depression.
    Schatzberg AF
    J Clin Psychiatry; 2000; 61 Suppl 10():31-8. PubMed ID: 10910015
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fluoxetine (prozac) in depresion of adults.
    Kocur J; Rydzynski Z; Duszyk S; Gruszczynski W; Trendak W
    Homeost Health Dis; 1991; 33(5-6):295. PubMed ID: 18265505
    [No Abstract]   [Full Text] [Related]  

  • 46. Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder.
    Meltzer H; Bastani B; Jayathilake K; Maes M
    Neuropsychopharmacology; 1997 Jul; 17(1):1-11. PubMed ID: 9194044
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
    Leinonen E; Skarstein J; Behnke K; Agren H; Helsdingen JT
    Int Clin Psychopharmacol; 1999 Nov; 14(6):329-37. PubMed ID: 10565799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.
    Coleman CC; King BR; Bolden-Watson C; Book MJ; Segraves RT; Richard N; Ascher J; Batey S; Jamerson B; Metz A
    Clin Ther; 2001 Jul; 23(7):1040-58. PubMed ID: 11519769
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Fluoxetine Collaborative Study Group.
    Small GW; Hamilton SH; Bystritsky A; Meyers BS; Nemeroff CB
    Int Psychogeriatr; 1995; 7 Suppl():41-53. PubMed ID: 8580391
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New developments in the treatment of depression.
    Montgomery SA
    J Clin Psychiatry; 1999; 60 Suppl 14():10-5; discussion 31-5. PubMed ID: 10408420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis.
    van den Broek WW; Mulder PG; van Os E; Birkenhäger TK; Pluijms E; Bruijn JA
    J Psychopharmacol; 2009 Aug; 23(6):708-13. PubMed ID: 18562424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluoxetine in the prevention of depressive recurrences: a double-blind study.
    Gilaberte I; Montejo AL; de la Gandara J; Perez-Sola V; Bernardo M; Massana J; Martin-Santos R; Santiso A; Noguera R; Casais L; Perez-Camo V; Arias M; Judge R;
    J Clin Psychopharmacol; 2001 Aug; 21(4):417-24. PubMed ID: 11476126
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant.
    Thompson C; Peveler RC; Stephenson D; McKendrick J
    Am J Psychiatry; 2000 Mar; 157(3):338-43. PubMed ID: 10698807
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Venlafaxine: new preparation. Just another antidepressant.
    Prescrire Int; 1998 Aug; 7(36):112-4. PubMed ID: 10342950
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fluoxetine. A pharmacoeconomic review of its use in depression.
    Wilde MI; Benfield P
    Pharmacoeconomics; 1998 May; 13(5 Pt 1):543-61. PubMed ID: 10180753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients.
    Diaz-Martinez A; Benassinni O; Ontiveros A; Gonzalez S; Salin R; Basquedano G; Martinez RA
    Clin Ther; 1998; 20(3):467-76. PubMed ID: 9663362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
    J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [SIADH with epileptic seizures and coma in fluoxetine therapy].
    Romerio SC; Radanowicz V; Schlienger RG
    Praxis (Bern 1994); 2000 Mar; 89(10):404-10. PubMed ID: 10731855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
    Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
    Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
    Fawcett J; Barkin RL
    J Affect Disord; 1998 Dec; 51(3):267-85. PubMed ID: 10333982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.